Helicos BioSciences Corp. 

(Public, NASDAQ:HLCS)   Watch this stock   
Find more results for HLCS
Nov 9, 2009
Q3 2009 HELICOS BIOSCIENCES CORP Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -624.17% -5649.88%
Operating margin -538.72% -5440.10%
EBITD margin - -5130.69%
Return on average assets -134.34% -100.70%
Return on average equity -293.08% -142.79%
Employees 71 -

Address

One Kendall Square Building 700
Cambridge, MA 02139
United States - Map
+1-617-2641800 (Phone)
+1-617-5514751 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Helicos BioSciences Corp. discussed on blogs

Stock Market Analysis: Largest Stock Losers - 11/20/09 - tweid05@gmail.com (stockstobuy.org) - Stock Market Analysis - Nov 20, 2009

Helicos BioSciences Corp. discussions

  View all discussions »

Description

Helicos BioSciences Corporation (Helicos) is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Helicos has developed a technology, called the True Single Molecule Sequencing (tSMS) technology, to facilitate the rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA). The Company's Helicos Genetic Analysis Platform obtains sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. It consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies.

Officers and directors

Stanley N. Lapidus
Chairman of the Board
Age: 59
Bio & Compensation - Reuters
Ronald A. Lowy
Chief Executive Officer, Director
Age: 53
Bio & Compensation - Reuters
Stephen J. Lombardi
President, Director
Age: 53
Bio & Compensation - Reuters
Jeffrey R. Moore
Chief Financial Officer, Senior Vice President, PFO and Principal Accounting Officer, Treasurer
Age: 48
Bio & Compensation - Reuters
J. William Efcavitch Ph.D.
Senior Vice President, Chief Technology Officer
Age: 55
Bio & Compensation - Reuters
Marc S. Levine
Senior Vice President - Product Development
Age: 50
Bio & Compensation - Reuters
Noubar B. Afeyan Ph.D.
Lead Independent Director
Age: 46
Bio & Compensation - Reuters
Brian G. Atwood
Director
Age: 56
Bio & Compensation - Reuters
Peter Barrett Ph.D.
Director
Age: 56
Bio & Compensation - Reuters
Robert F. Higgins
Director
Age: 62
Bio & Compensation - Reuters